Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease

Table 2 Echocardiographic parameters and systolic arterial pressure in all dogs, healthy dogs and dogs with different stages of MMVD

	All dogs	Healthy	Stage B1	Stage B2	Stage C
Number	149	49	45	13	42
LA/Ao	1.42 (1.17–1.89)	1.20 (1.08–1.39) ^‡§	1.26 (1.14–1.43) ^‡§	1.79 ± 0.22 ^§	2.31 (1.84–2.69)
LVEDDn	1.55 (1.35–1.86)	1.42 ± 0.18 ^‡§	1.39 (1.27–1.63) ^‡§	1.83 ± 0.22	2.00 ± 0.35
LVESDn	0.91 (0.78–1.05)	0.89 ± 0.15 ^§	0.86 ± 0.18 ^§	0.96 ± 0.14	1.04 (0.95–1.14)
E peak velocity (m/s)	0.83 (0.65–1.13)	0.67 ± 0.16 ^‡§	0.75 ± 0.17 ^‡§	0.97 ± 0.20 ^§	1.32 ± 0.32
A peak velocity (m/s)	0.70 (0.55–0.83)	0.59 ± 0.13 ^‡§	0.68 (0.54–0.82) ^§	0.76 (0.70–0.86)	0.81 (0.70–0.97)
E/A	1.23 (1.00–1.51)	1.17 ± 0.27 ^§	1.12 ± 0.30 ^§	1.20 ± 0.26 ^§	1.66 ± 0.55
SAP	142.94 ± 19.73	145 (140–150)	141.76 ± 20.62	155 (127.50–170)	140.67 ± 20.96

LA/Ao Left atrium-to-aortic root ratio, E/A E peak velocity-to-A peak velocity ratio, LVEDDn Normalized left ventricular end-diastolic diameter, LVESDn Normalized left ventricular end-systolic diameter, SAP Systolic arterial pressure
Data are reported as mean ± standard deviation for normally distributed variables and median (interquartile range) for non-normally distributed variables
†values significantly differ (p < 0.05) from stage B1; ‡values significantly differ (p < 0.05) from stage B2; §values significantly differ (p < 0.05) from stage C

ISSN: 1746-6148